Table 2.

Comparison between perioperative outcomes of patients undergoing MIMH with neoadjuvant versus no-neoadjuvant chemotherapy for colorectal liver metastases

		Entire unmatched cohort			1:1 coarsened exact matching			1:2 propensity-score matching
	All N = 1034	NAT (N = 641)	Non-NAT (N = 393)	P-value	NAT (N = 93)	Non-NAT (N = 93)	P-value	NAT (N = 334)	Non-NAT (N = 167)	P-value
Open conversion, n (%)	104 (10.1%)	71 (11.1%)	33 (8.4%)	0.164	9 (9.7%)	10 (10.8%)	0.819	39 (11.7%)	23 (13.8%)	0.502
Mean operating time (SD), min	315 (250–390)	312 (250–390)	318 (254–405)	0.575	305 (240–374)	322 (267–406)	0.319	306 (250–360)	311 (260–409)	0.222
Mean blood loss (SD), ml	300 (150–600)	300 (150–644)	300 (150–500)	0.135	300 (150–600)	250 (150–600)	0.136	300 (128–596)	250 (100–400)	0.047
Intraoperative blood transfusion, n (%)	155 (15.0%)	97 (15.1%)	58 (14.8%)	0.870	18 (19.4%)	11 (11.8%)	0.194	51 (15.3%)	28 (16.8%)	0.665
Pringle maneuver applied, n (%)	597/1015 (58.8%)	387/632 (61.2%)	210/383 (54.8%)	0.044	55 (59.1%)	54 (58.1%)	0.924	209/331 (63.1%)	99/164 (60.4%)	0.550
Mean postoperative stay, days (SD)	6 (4–8)	6 (4–8)	6 (5–9)	0.520	6 (4–8)	6 (4–9)	0.280	6 (4–8)	6 (5–9)	0.043
Postoperative morbidity, n (%)	320 (30.9%)	213 (33.2%)	107 (27.2%)	0.043	23 (24.7%)	28 (30.1%)	0.484	115 (34.4%)	54 (32.3%)	0.640
Major morbidity (Clavien-Dindo grade> 2)	129 (12.5%)	83 (12.9%)	46 (11.7%)	0.557	9 (9.7%)	12 (12.9%)	0.487	43 (12.9%)	24 (14.4%)	0.646
30-day mortality, n (%)	9 (0.9%)	6 (0.9%)	3 (0.8%)	0.772	0 (0.0%)	1 (1.1%)	0.317	6 (1.8%)	2 (1.2%)	0.620
90-day mortality, n (%)	17 (1,6%)	11 (1.7%)	6 (1.5%)	0.816	2 (2.2%)	2 (2.2%)	1.000	9 (2.7%)	4 (2.4%)	0.845

^*NAT-Neoadjuvant chemotherapy; SD - Standard Deviation;